UA-45667900-1

Friday, 20 November 2026

MARA autism: could maternal antibodies account for a sizeable subgroup of autism diagnoses?



Could maternal antibodies account for as much autism as all known single-gene conditions combined?

That is the striking possibility raised by research into maternal autoantibody-related autism (MARA). A prospective study found particular maternal antibody patterns in about 10% of mothers of autistic children, compared with about 1% of controls. Some reviews estimate that recognised single-gene disorders account for roughly 5–10% of autism. The numbers sit in a similar range—but the antibody finding is an association, not yet a proven cause.

If even part of this signal proves causal, MARA could be one of the larger identifiable non-genetic subgroups of autism. That makes it worth taking seriously, while being careful not to claim more than the evidence shows.


Summary


  • Core hypothesis: MARA proposes that in some pregnancies, maternal IgG antibodies targeting fetal brain proteins cross the placenta and disrupt neurodevelopment.
  • Human and animal signal: Cohort studies have linked specific antibody combinations with autism—including blood collected during pregnancy—and animal models add biological plausibility.
  • Scale vs. causation: A 10% vs. 1% prospective difference points to a potentially meaningful subgroup, but association alone does not prove causation.
  • Commercial & recurrence limits: Claims about commercial testing (including a 20% prevalence figure and “over 97%” risk) and high recurrence risk outrun published, peer-reviewed data.
  • Prevention status: Folinic acid is a testable hypothesis from folate-receptor-antibody work, not a proven prenatal preventive treatment.


1. The commercial MAR-Autism test: what is being offered, and at what cost?

Before looking at the underlying science, it helps to be clear about the commercial test driving much of the current attention. MARAbio Systems—a Salt Lake City biotech company built around intellectual property licensed from Judy Van de Water’s laboratory at UC Davis—markets a maternal blood test called MAR-Autism across most of the United States through healthcare providers and a partnered telehealth option.

  • Who it is for: It is marketed to mothers who already have a child diagnosed with autism or showing early signs of autism. It is not validated for prenatal screening, and the company states it is not intended for use during pregnancy.
  • What it measures and claims: Using a maternal blood draw only (no sample is taken from the child), the assay looks for specific combinations of antibodies against eight fetal brain proteins. Company materials state that roughly 20% of mothers of autistic children carry these antibody patterns and claim an “over 97%” risk of autism diagnosis.
  • How those claims compare with published data: The 20% figure is roughly double the 10% rate seen in the prospective mid-pregnancy EMA study (and the 10% validation figure in CHARGE). Similarly, an “over 97%” risk figure is hard to reconcile with published cohort proportions (~1% of controls vs. ~10% of case mothers), as cohort prevalence alone does not establish positive predictive value in a real-world population.
  • Cost and coverage: MARAbio lists an upfront cash price of $640 , which covers the collection kit, shipping, maternal blood draw, and lab analysis. It is not covered by health insurance, though itemized receipts may be submitted for HSA/FSA reimbursement, and the company offers a 4-month payment plan and income-based financial assistance.

In short, families are being offered an out-of-pocket test marketed around “pre-symptom support” and “informed family planning,” backed by strong headline numbers. The sections below examine what the peer-reviewed studies actually show—and where the evidence stops.


2. What MARA proposes

During pregnancy, the placenta actively transports maternal IgG antibodies to the fetus via the neonatal Fc receptor (FcRn), normally providing passive immunity. The MARA hypothesis suggests that certain antibodies can also bind proteins in the developing brain and interfere with neurodevelopment.

This points to a maternal immune characteristic rather than necessarily a pathogenic variant in the child, though genetics may still shape antibody production or fetal susceptibility. Crucially, mothers do not cause these antibodies through anything they do: this is not a parenting or lifestyle failing.


3. The evidence, in layers

Layer 1: human association (discovery)

Researchers led by Judy Van de Water at UC Davis have focused on antibodies against eight proteins: CRMP1, CRMP2, GDA, LDHA, LDHB, NSE, STIP1, and YBOX.

Single-protein reactivity is common; the reported signal centres on specific combinations. In the 2021 CHARGE study (450 case mothers, 342 controls), notable patterns included:

  • CRMP1 + GDA: 4.2% of case mothers vs. 0% of controls (OR 31.04)
  • CRMP1 + CRMP2: 3.6% vs. 0% (OR 26.08)
  • NSE + STIP1: 3.1% vs. 0% (OR 22.82)

Because control rates were 0%, those odds ratios are statistically unstable, and blood was drawn two to five years after birth rather than during gestation. The study also linked maternal CRMP1 reactivity to higher autism severity scores (OR 2.3, 95% CI 1.36–3.99). Patterns appeared in up to 18% of the discovery sample and 10% of the validation sample—with the validation figure offering the more cautious benchmark.


Layer 2: a prospective test

A 2022 Early Markers for Autism (EMA) study analysed stored maternal blood collected at 15–20 weeks of gestation across 540 autism mothers, 184 mothers of children with intellectual disability without autism, and 420 general-population controls:

  • At least one pattern: 10.2% (autism) vs. 3.8% (intellectual disability) vs. 1.4% (controls)
  • Autism vs. controls: OR 7.81 (95% CI 3.32–22.43)
  • Autism vs. intellectual disability: OR 2.77 (95% CI 1.19–7.47), with no significant difference between intellectual disability and controls
  • Top pattern: CRMP1 + CRMP2 (~2.6% of case mothers vs. 0% of controls)

Gestational sampling makes this the strongest human dataset so far, though several caveats apply:

  • CRMP1 + GDA and NSE + STIP1 were not statistically significant here.
  • Over half of mothers across groups reacted to at least one single antigen; specificity depended on combinations.
  • Controls were not confirmed to be exclusively typically developing.
  • Patent holdings and commercial test development by the senior author make independent replication especially important.


CHARGE vs. EMA at a glance

Feature CHARGE Study (2021) EMA Study (2022)
Sampling timing 2–5 years after birth 15–20 weeks during pregnancy (prospective)
Sample size ~450 autism mothers; 342 controls 540 autism; 184 ID (without autism); 420 controls
Any target pattern Up to 18% (discovery) / 10% (validation) 10.2% (autism) vs. 3.8% (ID) vs. 1.4% (controls)
Overall odds ratio — OR 7.81 vs. controls (95% CI 3.32–22.43)
OR 2.77 vs. ID (95% CI 1.19–7.47)
Top specific patterns CRMP1 + GDA: 4.2% vs. 0% (OR 31.04)
CRMP1 + CRMP2: 3.6% vs. 0% (OR 26.08)
NSE + STIP1: 3.1% vs. 0% (OR 22.82)
CRMP1 + CRMP2: ~2.6% vs. 0% controls
(CRMP1 + GDA and NSE + STIP1 not significant)
Key limitations Post-natal blood draw; 0% controls make ORs statistically unstable Over half of mothers across all groups had single-antigen reactivity; control developmental status unconfirmed


Layer 3: animal experiments

Experimental models add mechanistic plausibility while remaining preliminary:

  • Non-human primates: Small rhesus-monkey studies using IgG from mothers of autistic children reported increased stereotypies and hyperactivity, with later work noting differences in brain growth and social development.
  • Rodents: Passive-transfer mouse and rat studies have reported behavioural shifts, including a 2025 rat study showing marked gene-expression changes after CRMP1 + CRMP2 exposure. An Oxford group separately found that maternal CASPR2 antibodies altered microglia and offspring behaviour in mice.

Small primate sample sizes, pooled or mixed antibody preparations, and overlapping research networks mean these findings support plausibility rather than proving human causation.

Layer 4: independent groups and dissent

Findings across independent teams are mixed:

  • Researchers at Hasselt University reported antibodies to a different four-protein panel in 16% of autism mothers vs. 4% of controls—supporting the broad concept without replicating the UC Davis eight-protein patterns.
  • An Oxford group linked maternal CASPR2 antibodies to intellectual disability rather than autism, saw no excess of NMDA-receptor antibodies, and concluded in a 2020 review that MARA likely accounts for a relatively small fraction of cases.

Broadly, multiple groups see evidence that maternal antibodies can influence fetal brain development, but the specific eight-protein patterns and their claimed subgroup size still require independent replication.


4. How common is it really?

Reported figures measure different things and shouldn't be treated as interchangeable:

  • CHARGE: up to 18% (discovery) and 10% (validation), measured years post-birth.
  • EMA: 10% vs. 1% during mid-pregnancy in one California cohort sampled in the early 2000s.
  • Company materials: around 20%.

Even with a ~9-percentage-point difference in EMA, observational association cannot be read directly as causal share without ruling out confounding and establishing causality. Still, comparing the ~10% prospective figure to rough 5–10% estimates for recognised single-gene conditions is useful as a scale benchmark—showing why MARA merits serious study if even part of the effect is causal, while leaving true population prevalence unknown.


5. Recurrence: the November 2026 announcement

In November 2026, MARAbio reported that CHARGE-linked antibody combinations also appeared in the MARBLES cohort and were associated with high recurrence in later-born siblings. Because the announcement did not publish sample sizes, recurrence percentages, confidence intervals, or peer-reviewed data, its predictive value cannot yet be verified.

In Baby Siblings Research Consortium data (2011 and 2024), baseline autism recurrence in younger siblings is already roughly 19–20%. For recurrence testing to add real clinical value, it must meaningfully outperform family history—something unpublished summary claims cannot yet demonstrate.


6. Folate receptor autoantibodies: the closest relative of MARA

Folate receptor alpha (FRα) autoantibodies operate through a different mechanism—potentially blocking folate transport across the choroid plexus into the brain and causing cerebral folate deficiency despite normal blood folate—but represent a closely watched neighbouring area. Because FRα antibodies also appear in some siblings and parents, they are not specific to autism.

In rats, gestational FRα-antibody exposure produced offspring behavioural changes that folinic acid reduced in one model. A 2021 review suggested studying folinic acid alongside standard folic acid in antibody-positive pregnancies, and EpiphanyASD has noted one clinician prescribing folinic acid to prospective parents who test positive—but controlled human pregnancy prevention trials do not exist.

Two distinct clinical questions are often conflated and need to stay separate:

  • Treating autistic children: In March 2026, the FDA approved leucovorin for cerebral folate transport deficiency due to a confirmed FOLR1 mutation—not for autism broadly, citing insufficient evidence of efficacy—while the largest randomised leucovorin trial in autistic children (Panda et al.) was retracted in January 2026, and the Child Neurology Society has stated that FRα-antibody status is not a validated predictor of treatment response.
  • Prenatal prevention: Whether maternal FRα antibodies affect fetal development and whether folinic acid can prevent that remains an open question for controlled research rather than an established prenatal practice.


7. Other prenatal mechanisms, and how they differ

  • Maternal immune activation (MIA): Animal models show that maternal infection or immune stimulation (involving signals such as IL-6 and IL-17A) can alter offspring development, though human infection and cytokine findings are mixed and MIA does not necessarily involve antibodies.
  • PANS and PANDAS: Proposed post-infectious, sudden-onset neuropsychiatric syndromes that can occur in autistic individuals, but differ from prenatal antibody transfer because they reflect post-natal immune processes and are not established autism subtypes.
  • Medication and environmental exposures: Valproate carries well-established gestational risk—a 2025 meta-analysis of eight cohorts (>6 million pregnancies) found an adjusted autism hazard ratio of 3.10, rising at higher doses—yet anyone taking valproate must consult their prescriber rather than stopping abruptly, given the serious risks of uncontrolled seizures. Other environmental exposures (air pollution, pesticides, metals) have more variable evidence.


8. Could these mechanisms interact?

Interactions between maternal antibodies and broader inflammation or metabolic factors are plausible, but early data remain tentative. A small EMA comparison (37 antibody-positive vs. 37 antibody-negative autism mothers) found higher interferon-gamma and a more inflammatory cytokine profile in the antibody-positive group, and an exploratory CHARGE analysis linked gestational diabetes with higher antibody prevalence in a severe-symptom subgroup (measured years post-pregnancy). None of these findings establishes direction of causality or explains individual pregnancies.


9. Can the risk be reduced?

Established standard care

  • Follow routine prenatal care: manage fever and infection, avoid alcohol, and review medications with a clinician before and during pregnancy.
  • Take standard prenatal folic acid.
  • Where clinically appropriate and guided by the prescribing doctor, avoid valproate during pregnancy.

These measures support general maternal and fetal health, though none is proven to prevent autism specifically.

Antibody-specific ideas (unproven / experimental)

  • Prenatal testing (unvalidated): Requires a test proven reliable for gestational use.
  • Broad antibody reduction (untested for MARA / non-selective): Plasmapheresis and IVIG are used in other antibody-mediated conditions, not validated here.
  • FcRn blockade (investigational / off-target to MARA): Agents like nipocalimab reduced maternal IgG in a small phase 2 trial for severe fetal haemolytic disease, showing technical feasibility rather than MARA suitability—and lowering maternal IgG carries potential trade-offs for newborn passive immunity.
  • Decoy/neutralising molecules (hypothetical): Early conceptual stage.
  • Targeting upstream triggers (preliminary): Cytokine and metabolic clues are too early to guide intervention.
  • Folinic acid for FRα antibodies (research hypothesis): Supported by rodent data, not controlled human pregnancy prevention trials.

None of these antibody-targeted approaches is ready for routine or self-directed use; pregnancy treatment choices belong with the pregnant individual and their clinical team.


10. What would settle the question

  • Independent, blinded replication of the eight-protein combinations in new cohorts.
  • Full peer-reviewed publication of CHARGE and MARBLES recurrence rates, denominators, and confidence intervals benchmarked against the 19–20% sibling baseline.
  • Longitudinal pre-pregnancy and across-pregnancy measurements to test pattern stability and true incremental predictive value over family history.
  • Direct studies linking maternal and cord-blood antibodies (including FRα) to developmental outcomes, followed by properly controlled trials before any preventive intervention is recommended.


Conclusion

MARA is a serious, testable hypothesis with a prospective human signal (10% vs. 1% in EMA) and animal data that make biological interference plausible. Its numerical scale is comparable enough to single-gene autism estimates to warrant careful investigation, yet association is not causation, replication and recurrence data remain incomplete, and prenatal interventions like folinic acid remain research questions rather than proven prevention.

Ultimately, MARA sits as one potential piece within a multifactorial landscape alongside genetics, other prenatal factors, and pathways still unknown.



For anyone wondering how much actual science underlies MARA autism here is an AI generated list of relevant references

Ramirez-Celis A, Becker M, Nuño M, Schauer J, Aghaeepour N, Van de Water J. Risk assessment analysis for maternal autoantibody-related autism (MAR-ASD): a subtype of autism. Mol Psychiatry. 2021;26:1551–1560. PMID 33483694. doi:10.1038/s41380-020-00998-8

Ramirez-Celis A, Croen LA, Yoshida CK, et al. Maternal autoantibody profiles as biomarkers for ASD and ASD with co-occurring intellectual disability. Mol Psychiatry. 2022;27:3760–3767. PMID 35618885. doi:10.1038/s41380-022-01633-4

Braunschweig D, Ashwood P, Krakowiak P, et al. Autism: maternally derived antibodies specific for fetal brain proteins. Neurotoxicology. 2008. PMID 18078998.

Martin LA, Ashwood P, Braunschweig D, Cabanlit M, Van de Water J, Amaral DG. Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. Brain Behav Immun. 2008;22:806–816.

Bauman MD, Iosif AM, Ashwood P, et al. Maternal antibodies from mothers of children with autism alter brain growth and social behavior development in the rhesus monkey. Transl Psychiatry. 2013;3:e278. doi:10.1038/tp.2013.47

Bruce MR, et al. Altered behavior, brain structure, and neurometabolites in a rat model of autism-specific maternal autoantibody exposure. Mol Psychiatry. 2023;28. PMID 36973347. doi:10.1038/s41380-023-02020-3

Gestational autoantibody exposure impacts early brain development in a rat model of MAR autism. Mol Psychiatry. 2025;30:3018–3028. doi:10.1038/s41380-025-02907-3

Marks K, Coutinho E, Vincent A. Maternal-autoantibody-related (MAR) autism: identifying neuronal antigens and approaching prospects for intervention. J Clin Med. 2020;9:2564. PMID 32784803. doi:10.3390/jcm9082564

Coutinho E, Jacobson L, Pedersen MG, et al. CASPR2 autoantibodies are raised during pregnancy in mothers of children with mental retardation and disorders of psychological development but not autism. J Neurol Neurosurg Psychiatry. 2017;88:718.

Novel maternal autoantibodies in autism spectrum disorder: implications for screening and diagnosis (Hasselt University). Front Neurosci. 2023. PMID 36816132. doi:10.3389/fnins.2023.1067833

McLellan J, Croen L, Iosif AM, Yoshida C, Ashwood P, Yolken RH, Van de Water J. Altered cytokine and chemokine profile linked to autoantibody and pathogen reactivity in mothers of autistic children. Front Psychiatry. 2024;15:1348092. doi:10.3389/fpsyt.2024.1348092

Krakowiak P, Walker CK, Tancredi D, Hertz-Picciotto I, Van de Water J. Autism-specific maternal anti-fetal brain autoantibodies are associated with metabolic conditions. Autism Res. 2017;10(1):89–98. doi:10.1002/aur.1657. PMID 27312731.

MARAbio Systems. New clinical findings linking maternal autoantibodies to a non-genetic form of autism and high familial recurrence risk. Press release, 16 November 2026. Full recurrence data unpublished. Coverage: Contemporary Pediatrics, November 2026.

Ozonoff S, Young GS, Carter A, et al. Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study. Pediatrics. 2011;128:e488–e495. PMID 21844053. doi:10.1542/peds.2010-2825

Ozonoff S, et al. Familial recurrence of autism: updates from the Baby Siblings Research Consortium. Pediatrics. 2024;154(2). doi:10.1542/peds.2023-065297

Desai A, Sequeira JM, Quadros EV. Prevention of behavioral deficits in rats exposed to folate receptor antibodies: implication in autism. Mol Psychiatry. 2017;22:1291–1297. doi:10.1038/mp.2016.153

Moise KJ Jr, Ling LE, Oepkes D, et al. Nipocalimab in early-onset severe hemolytic disease of the fetus and newborn. N Engl J Med. 2024;391:526–537.

Brynge M, Gardner RM, Sjöqvist H, Lee BK, Dalman C, Karlsson H. Maternal levels of cytokines in early pregnancy and risk of autism spectrum disorders in offspring. Front Public Health. 2022;10:917563. doi:10.3389/fpubh.2022.917563


Friday, 13 November 2026

PIEZO: How a high-school physics concept became relevant to osteoporosis, Alzheimer's and autism

From quartz crystals and electrical charges to bone formation, sensory processing and the brain's waste-disposal system.

 

From high school to the research lab

 

Key points

•        PIEZO1 and PIEZO2 are proteins that let cells sense physical force. Despite the name, they are not piezoelectric crystals: they are mechanically activated ion channels.

•        In bone, PIEZO1 helps osteocytes respond to mechanical loading. In aged mice, activating it restored the bone response, but only when combined with loading.

•        In mouse models of autism, PIEZO2 has been linked to tactile hypersensitivity and to oxytocin signalling. Evidence in autistic people is still missing.

•        In the brain, PIEZO1-related signalling has been linked both to improved fluid transport (ultrasound in Alzheimer's mice) and to synapse loss triggered by bacterial lipopolysaccharide (LPS) in mice. These results look contradictory, and they suggest a "Goldilocks" receptor: not too little, not too much.

•        A small human study of a vibrating mattress combined with nitric oxide raised blood levels of brain-derived Alzheimer's proteins. This may indicate increased waste clearance from the brain, which could be very beneficial.

 

A reason to pay attention in physics class

There is a connection between a principle taught in high-school physics and some of the more interesting developments in modern medicine.

The piezoelectric effect describes how certain materials generate an electrical charge when mechanical pressure is applied. More than a century later, scientists found that our own cells contain specialised proteins that detect mechanical forces and convert them into electrical and biochemical signals. They are called PIEZO channels, from the Greek piezein, to squeeze or press.

A clarification is needed at the start. PIEZO channels are not piezoelectric crystals, and they do not generate charge in the way quartz does. They are proteins in the cell membrane that open when the membrane is stretched or deformed, letting ions flow in. The name reflects a shared idea (force in, electrical signal out) rather than a precisely shared physical mechanism.

Research into these channels is opening up connections between exercise and bone strength, sensory processing in autism, oxytocin signalling and the movement of fluid through the brain. Sometimes the physics lesson you thought you would never use turns out to be relevant to some of the more interesting questions in medicine.


From piezoelectric crystals to biological sensors

The piezoelectric effect was discovered in 1880 by the French physicists Pierre and Jacques Curie. They showed that pressure applied to certain crystals, including quartz, could generate an electrical charge. The reverse effect also occurs: applying an electrical field can make certain materials change shape.

In 2010, a team in Ardem Patapoutian's laboratory identified two previously unknown mechanically activated ion channels, named PIEZO1 and PIEZO2. Patapoutian shared the 2021 Nobel Prize in Physiology or Medicine with David Julius for discoveries concerning receptors for temperature and touch.

PIEZO proteins sit within cell membranes. When a cell is stretched, compressed or otherwise mechanically deformed, these channels can open, allowing positively charged ions, particularly calcium, to enter the cell. This converts a physical force into an electrical and biochemical signal. The process is known as mechanotransduction.

PIEZO1 and PIEZO2 have different distributions and functions. PIEZO1 is particularly important in blood vessels, lymphatic vessels and bone. PIEZO2 is especially important in sensory neurons, where it helps us detect touch, pressure, body position and movement.

The distinction matters because the same general mechanism can have very different consequences depending on which cells express the channel, and, as we will see, on the context.


1. PIEZO1 and osteoporosis: why mechanical loading matters

Bone is not an inert structure. It is living tissue that constantly remodels itself in response to mechanical demands.

One of the most important cells involved is the osteocyte. These cells are embedded within the bone matrix and act as sensors, detecting mechanical loading and the movement of fluid through the tiny channels surrounding them.

When we walk, run, jump or lift weights, forces are transmitted through bone. Osteocytes detect these forces and communicate with other bone cells, helping regulate the balance between bone formation and bone resorption.

PIEZO1 appears to be an important part of this sensing mechanism. When mechanical forces activate PIEZO1 in osteocytes, calcium enters the cells and triggers downstream signalling, including pathways involving Wnt signalling, and other regulators of bone remodelling.

One consequence is the regulation of sclerostin, a protein that normally inhibits bone formation. Mechanical loading can reduce sclerostin signalling, allowing bone-building activity to increase. This helps explain why appropriate mechanical loading is so important for maintaining bone density.


Does the response to PIEZO1 weaken with age?

A study published in August 2026 examined why older bone becomes less responsive to mechanical stimulation.

The researchers used 19-month-old mice and found that their bones had a blunted anabolic response to mechanical loading. Giving Yoda1, a chemical compound that activates PIEZO1, was also insufficient on its own. However, combining Yoda1 with mechanical loading restored the anabolic response in aged cortical bone.

The research findings suggest that age-related changes in how osteocytes respond to mechanical forces may be partly overcome by enhancing PIEZO1 signalling while providing an appropriate mechanical stimulus.

The distinction matters: the study does not show that PIEZO1 simply disappears with age. It shows that the bone's response to mechanical stimulation becomes less effective, and that PIEZO1 activation can help restore that response.

Yoda1 is a research compound, not an approved osteoporosis treatment, and the findings are from mice, so we cannot yet assume the same approach will work in people. The result does offer a molecular explanation for why mechanical loading matters, and it raises the possibility that future osteoporosis treatments might combine mechanical stimulation with drugs that help bone cells sense that stimulation.


2. PIEZO2 and autism: could sensory hypersensitivity involve mechanical sensing?

Many autistic people have unusual sensory responses. Touch, pressure, clothing, hair brushing, light contact or unexpected physical contact can be uncomfortable or even painful.

The mechanisms are complex. They may involve sensory receptors, peripheral nerves, spinal processing and the way the brain interprets incoming signals. PIEZO2 is a natural candidate for investigation because it is one of the principal proteins responsible for detecting mechanical stimuli.

Human genetic studies have already shown how important PIEZO2 is. People with rare loss-of-function mutations can have profound difficulties with proprioception, the sense of where their body is in space, as well as abnormalities in discriminative touch. This establishes that PIEZO2 is essential for normal human mechanosensation. It does not establish that PIEZO2 abnormalities are a general cause of autism.


PIEZO2 and tactile hypersensitivity in an autism mouse model

A 2025 investigated PIEZO2 in BTBR mice, a commonly used animal model of autism.

The researchers found increased IGF-1 signalling in dorsal root ganglia, clusters of sensory nerve cells outside the spinal cord. IGF-1 appeared to regulate PIEZO2 expression, and they identified an IGF-1-PIEZO2 pathway associated with tactile hypersensitivity. Interfering with this pathway reduced tactile hypersensitivity and also improved some social behaviours in the mice. A gentle-touch intervention reduced the abnormal expression of IGF-1 and PIEZO2 in sensory ganglia and improved the measured behavioural outcomes.

There are three implications. First, sensory hypersensitivity may not be only a problem of how the brain processes sensory information; some of the difference may originate further down the sensory pathway, in the peripheral nervous system. Second, excessive activation or expression of a mechanosensory pathway could contribute to an exaggerated response to ordinary physical stimuli. Third, it raises the question of whether different forms of tactile stimulation could influence sensory signalling.


PIEZO2, oxytocin and social behaviour

A study in July 2025 asked whether mechanical stimulation could influence oxytocin-producing neurons in the hypothalamus, a brain region involved in social behaviour, stress responses and hormonal regulation.

The researchers injected superparamagnetic iron oxide nanoparticles directly into the paraventricular nucleus of the hypothalamus in mice. A rotating magnetic field then produced mechanical stimulation, and the results depended on frequency. At 10 Hz, the system increased PIEZO2 expression in oxytocin-producing neurons, leading to calcium influx and increased oxytocin signalling. In mice exposed to valproic acid during development, an experimental autism model, the intervention improved several autism-like behavioural measures. When the researchers reduced PIEZO2 expression, the beneficial effects were lost, which suggests PIEZO2 was part of the mechanism linking mechanical stimulation to oxytocin release.


Is PIEZO1 itself an autism-related gene?

There are also some emerging genetic and epigenetic observations involving PIEZO1.

A 2026 study analysed de novo genetic variants in 41,367 parent-child trios from three family-based cohorts. PIEZO1 appeared among a group of genes showing statistically significant male-specific enrichment in one of the gene-based analyses. This is potentially relevant given autism's well-known sex bias. But it is a preprint that has not yet been peer reviewed, the study included both affected and unaffected individuals, and the findings do not establish PIEZO1 as a recognised high-confidence autism gene. It is a candidate for further investigation.

A separate 2025 study examined DNA methylation of PIEZO1 in infants with neurodevelopmental disorders. The researchers studied 24 infants with neurodevelopmental disorders and 22 typically developing infants, and found lower methylation at a group of PIEZO1 sites in the clinical group. Methylation can influence gene regulation, so this raises the possibility that PIEZO1 expression is altered during early neurodevelopment. But the clinical group was a mixture of conditions rather than autism alone, methylation was measured in buccal cells rather than brain tissue, and the researchers did not measure PIEZO1 gene or protein expression. It is an early observation, not evidence of a specific autism mechanism.


What does this mean for autism?

We now have several separate lines of research:

•        PIEZO2 may contribute to tactile hypersensitivity through sensory neurons outside the brain (mice).

•        PIEZO2 may influence oxytocin release through hypothalamic neurons (mice).

•        PIEZO1 has appeared in a large genetic analysis as a candidate requiring further investigation.

•        PIEZO1 methylation differences have been reported in a small group of infants with neurodevelopmental disorders.

These findings suggest that mechanosensitive ion channels may be relevant to several biological processes already of interest in autism research, and different individuals or subgroups could have quite different alterations.

Where this leaves us. The most informative next steps would be human studies that measure tactile detection and discomfort thresholds in autistic participants alongside PIEZO2 genotyping or expression data; peer-reviewed replication of the PIEZO1 de novo variant signal; and replication of the methylation finding in larger, autism-specific groups. Until then, PIEZO2 is a plausible mechanism for some sensory differences, not an established one.


3. PIEZO1, brain pulsations and Alzheimer's disease

The brain has its own system for moving fluid and clearing waste products, commonly referred to as the glymphatic system. It involves the movement of cerebrospinal fluid (CSF) along pathways surrounding blood vessels, with exchange between CSF and fluid in the brain tissue. Waste products, including soluble amyloid-beta, can then be carried towards drainage pathways. The system appears to be particularly active during sleep.

The glymphatic concept is still debated. Some researchers question how much fluid is moved by bulk flow rather than diffusion, how reliably clearance can be measured in humans, and whether sleep and anaesthesia change it in the way early mouse studies suggested. 

Why does PIEZO1 matter here? Blood vessels constantly expand and contract in response to changes in blood pressure and flow, and these movements create mechanical forces that can influence the surrounding fluid. PIEZO1 is expressed in vascular endothelial cells, which line blood vessels, and lets them detect mechanical forces and change their signalling. This provides a possible link between vascular pulsations, mechanical stimulation and the movement of fluid through the brain. If these processes become less effective with age, the clearance of soluble proteins could be affected, which would be relevant to Alzheimer's disease, where accumulation of amyloid-beta and other abnormal proteins is a major feature.


Ultrasound activates a PIEZO1-related pathway in Alzheimer's mice

A 2026 study investigated whether low-intensity focused ultrasound could improve glymphatic-associated transport in 5xFAD mice, a widely used Alzheimer's disease model. The researchers applied ultrasound to the hippocampal region over four weeks.

They reported increased CSF tracer movement into the brain and improved transport of solutes through brain tissue. They also found increased soluble amyloid-beta in deep cervical lymph nodes, reduced amyloid deposits in the hippocampus and prefrontal cortex, and improvements in learning and memory tests. The effects were accompanied by increased PIEZO1 signalling in brain vascular tissue, and when the researchers inhibited PIEZO1-related signalling, many of the benefits were reduced.

This is experimental evidence that PIEZO1-related mechanotransduction may contribute to the effects of ultrasound on brain fluid transport. It remains an animal study and does not show that ultrasound can prevent or treat Alzheimer's disease in humans.


PIEZO1, gut bacteria and microglia: a double-edged sword?

So far PIEZO1 has appeared as a helpful sensor: it helps bone respond to loading, and its activation was linked to better fluid transport in the ultrasound study. A 2025 paper suggests the picture is less simple.

The researchers were interested in lipopolysaccharide (LPS), a component of the outer wall of Gram-negative bacteria and a powerful inflammatory trigger. LPS has been found at higher levels in Alzheimer's brains, but it is not clear how it gets past the blood-brain barrier. One suggestion is that it travels inside bacterial extracellular vesicles (bEVs), tiny membrane packages released by gut bacteria.

The team isolated bEVs from the faeces and blood of people and mice. LPS levels in these vesicles, or in plasma vesicles overall, were higher in people with Alzheimer's disease or mild cognitive impairment than in healthy controls. In mice, vesicles from Gram-negative bacteria reached the brain, while those from Gram-positive bacteria did not. Neutralising the LPS, or using bacteria engineered to lack it, prevented the vesicles from getting in.

Once in the brain, the vesicles activated microglia, raised levels of the complement proteins C1q and C3, and led to loss of synapses within 24 hours, with microglia engulfing more synaptic material. PIEZO1 was involved. The vesicles increased Piezo1 and calcium levels in microglial cells, and blocking Piezo1 with the inhibitor GsMTx4 reduced the effect. Mice lacking Piezo1 in myeloid cells (the cell family that includes microglia) were largely protected from the synapse loss. Samples of Alzheimer's cortex also showed more Piezo1 in microglia.

This looks very different from earlier work. A 2023 study in cultured microglia found that activating PIEZO1 with Yoda1 reduced LPS-induced inflammation, and other work suggests PIEZO1 may help microglia engulf amyloid plaques. The authors of the new paper themselves describe PIEZO1 as a "double-edged sword".

Several cautions apply. Most experiments were short-term injections of vesicles into young mice, with synapse counts at 24 hours. There were no memory tests and no chronic Alzheimer's model, and several comparisons used only three animals per group. GsMTx4 is a non-specific inhibitor and only partly blocked the effects. Here PIEZO1 seems to be switched on by vesicle uptake and inflammation rather than by physical force, so this is not mechanotransduction in the usual sense. It is a mouse and cell-culture mechanism, not a treatment.

It does carry a lesson for the rest of this post: boosting PIEZO1 in one tissue says little about what it will do in another. I return to this in Section 6.

Thanks to our reader Stephen for suggesting a post on LPS and PIEZO1.


4. The vibrating mattress: a new human study

The story took another turn with a study published in November 2026. Researchers investigated a combination of nitric oxide-mediated vasodilation and a specially designed whole-body vibration intervention intended to stimulate PIEZO1. The study involved 29 healthy adults.

The vibration was delivered with a commercially available Neurosonic Mobile Mattress, using a specially modulated vibration pattern rather than simple continuous vibration. The researchers also gave a sublingual nitric oxide intervention. Nitric oxide causes blood vessels to relax and dilate, while mechanical stimulation of PIEZO1 can produce complementary changes in vascular signalling. The idea was to influence the movement of blood and fluid through the brain by combining the two mechanisms. Nitric oxide is a recurring theme on this blog, including the vascular effects of agmatine and eNOS.

Following the combined intervention, the researchers measured increases in blood levels of several brain-derived proteins:

•        Amyloid-beta 40 (Aβ40)

•        Amyloid-beta 42 (Aβ42)

•        Glial fibrillary acidic protein (GFAP)

They also observed changes in MRI measurements of brain fluid dynamics and brain pulsations. A similar rise in blood levels of brain-derived proteins was reported after intermittent hypercapnia, which I discussed in July so the mattress result fits a developing pattern in which vascular oscillations are associated with proteins appearing in the blood.


What the study does and does not show

The increases in circulating proteins are consistent with a temporary movement of soluble brain-derived proteins towards the bloodstream. That is a hypothesis, not the only possible reading. Release from blood cells or the vessel wall, the haemodynamic effects of vasodilation and a falling blood pressure, or, in the case of GFAP, an astroglial stress response could all contribute. Telling these apart would need studies that measure clearance directly, follow the proteins over a longer period and include control interventions.

The effect was also acute. A rise in blood proteins after a single session does not show net clearance from the brain over time. An increase in amyloid-beta in the blood does not prove that amyloid plaques have been removed, and it does not demonstrate better memory, reduced Alzheimer's risk or any clinical benefit. The study was small and involved healthy volunteers, not people with Alzheimer's disease.

It is nonetheless a first human indication that a PIEZO1-targeted mechanical intervention may influence brain fluid dynamics and the movement of brain-derived proteins, and a bridge between laboratory work on PIEZO1 and the possibility of non-pharmacological ways to influence brain fluid transport.


5. Could glymphatic dysfunction also be relevant to autism?

This brings us back to a question I have raised before on this blog: could impaired glymphatic drainage be relevant to autism?

A study in August 2026 adds a piece of evidence. Researchers analysed MRI data from five cohorts in the Autism Brain Imaging Data Exchange, involving 250 participants: 128 autistic individuals and 122 neurotypical controls. They used diffusion tensor imaging analysis along the perivascular space (DTI-ALPS), an indirect MRI measure that estimates water diffusion along pathways associated with blood vessels. It is sometimes used as a proxy for glymphatic function, although it does not directly measure clearance of waste products from the brain.

They found lower ALPS index values in the autistic group overall. The difference was particularly apparent in adults: there was no significant group difference among participants younger than 18, whereas autistic adults had lower values than neurotypical adults. Among autistic adults, the ALPS index was also associated with depressive symptoms, but not with IQ or the measured severity of autistic traits.

How this fits with earlier findings

In July I discussed a study of 78 autistic children and 48 typically developing controls that reported reduced DTI-ALPS values in children. The August analysis found no significant difference under 18, so the picture in children is not yet consistent. Differences in cohorts, scanners, age ranges and analysis methods could all contribute, and taken together the studies suggest a possible difference rather than an established one.

The interpretation needs care. The August study was cross-sectional, so it cannot tell us whether reduced perivascular fluid movement contributes to autism, develops later in life, or reflects other factors. Sleep, vascular function, mood and other health factors could all be relevant, and DTI-ALPS is an indirect marker rather than a direct measurement of glymphatic clearance.

If future studies confirm that some autistic people have altered glymphatic function, it would be worth asking whether this is associated with sleep disturbances, vascular differences or other biological features, and whether interventions that influence vascular pulsations or mechanical signalling have any relevance. At present, there is no evidence that vibrating mattresses or other PIEZO-targeted interventions improve glymphatic clearance in autistic people.


6. One principle, many applications: a Goldilocks receptor

What makes PIEZO research so interesting is that one biological mechanism lets physical forces influence very different systems. In bone, mechanical loading helps osteocytes regulate bone formation. In the peripheral nervous system, PIEZO2 helps detect touch, pressure and body position. In the hypothalamus, PIEZO2 can influence oxytocin-producing neurons. In blood vessels and lymphatic vessels, PIEZO1 helps cells respond to mechanical forces. And in the brain, these processes may influence the movement of fluid and the clearance of soluble proteins.

It is tempting to think of PIEZO channels as a universal switch that could be turned up to improve health. The evidence points the other way. PIEZO looks more like a Goldilocks receptor: not too little, not too much.

•        Bone: Yoda1 alone did not restore the response in aged mouse bone. It worked when combined with mechanical loading, so the stimulus and the channel both mattered.

•        Microglia: In cultured microglia, activating PIEZO1 with Yoda1 reduced LPS-induced inflammation. In mice, LPS-carrying bacterial vesicles activated microglial Piezo1 and drove synapse loss. Same channel, opposite-looking outcomes.

•        Stimulus: In the oxytocin study the effect depended on frequency, and only 10 Hz produced the described benefit.

The effects depend on which PIEZO channel is involved, which cells express it, the intensity, timing and frequency of stimulation, and the biological context. Too little activity may be a problem in one tissue, while excessive or prolonged activation could be harmful in another. I would treat "Goldilocks" as a working hypothesis rather than a finding: the studies show opposite effects in different settings, but none has mapped a dose-response curve for PIEZO activity.

The research also shows why mechanical stimulation is attracting renewed interest. Exercise, vibration, ultrasound and other physical inputs may have biological effects beyond moving muscles or loading bones, because they can influence how cells sense and respond to their physical environment. Regular exercise remains the simplest and best-supported way to apply mechanical stimulus to bone, and I have discussed how exercise may relate to glymphatic function [link: 22 July 2026 post].


Conclusion

The discovery of PIEZO channels created an unexpected bridge between physics and biology. A principle first demonstrated in crystals more than 140 years ago has a biological counterpart in proteins that let cells convert mechanical forces into electrical and chemical signals.

For osteoporosis, PIEZO1 helps explain how bones detect mechanical loading and why that response can become less effective with age. For autism, PIEZO2 research offers possible mechanisms for tactile hypersensitivity and oxytocin signalling, PIEZO1 deserves further investigation, and the MRI findings raise the question of whether altered brain fluid transport matters for some people. For Alzheimer's disease, animal studies and a small human study suggest that mechanical stimulation of vascular PIEZO1 pathways may influence brain fluid dynamics, while the LPS work is a reminder that the same channel can contribute to harm in another context.

Perhaps there really was a good reason to pay attention in physics class.

 

Selected research papers

PIEZO channels and mechanotransduction

•        Coste B. et al. (2010). Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. Science. DOI: 10.1126/science.1193270

•        Chesler A.T. et al. (2016). The Role of PIEZO2 in Human Mechanosensation. New England Journal of Medicine. DOI: 10.1056/NEJMoa1602812

Bone and osteoporosis

•        Zhao D. et al. (2026). Piezo1 Activation Rescues Anabolic Response to Mechanical Loading in Aged Bone via Connexin 43 Hemichannels. Aging Cell. DOI: 10.1111/acel.70687

Autism and sensory processing

•        Zhai J. et al. (2025). The effect of modulation Piezo2 by IGF-1 on tactile hypersensitivity in BTBR model mice. Life Sciences. DOI: 10.1016/j.lfs.2025.123449

•        Liu S. et al. (2025). PIEZO2 is the underlying mediator for precise magnetic stimulation of PVN to improve autism-like behavior in mice. Journal of Nanobiotechnology. DOI: 10.1186/s12951-025-03557-x

•        Turner T.N. (2026). De Novo Variation in Autism by Sex and Diagnostic Status in 41,367 Parent-Child Trios. medRxiv preprint. DOI: 10.64898/2026.01.26.26344889

•        Mascheroni E. et al. (2025). Exploring PIEZO1 DNA methylation in infants with neurodevelopmental disorders. Frontiers in Psychology. DOI: 10.3389/fpsyg.2025.1593609

Alzheimer's disease, microglia and glymphatic transport

•        Zhang L. et al. (2026). Ultrasound enhances glymphatic-associated solute transport via Piezo1-related mechanotransduction in 5xFAD mice. Journal of Cerebral Blood Flow & Metabolism. DOI: 10.1177/0271678X261470064

•        Tuunanen J. et al. (2026). Vasomechanic treatment is associated with increased efflux of human brain proteins. Nature Communications. DOI: 10.1038/s41467-026-78894-y

•        Zhao X., Yu J. et al. (2025). Gut-derived bacterial vesicles carrying lipopolysaccharide promote microglia-mediated synaptic pruning. Alzheimer's & Dementia. DOI: 10.1002/alz.70331

•        Piezo1 channel-mediated Ca2+ signalling inhibits LPS-induced activation of the NF-kB inflammatory signalling pathway and generation of TNF-alpha and IL-6 in microglial cells. Glia (2023), 71(4):848-865. [author list to be added]

•        The mechanosensitive Piezo1 channel mechanism of Alzheimer's disease and implications for the development of therapeutic or early detection strategies. Frontiers in Aging Neuroscience (2025). DOI: 10.3389/fnagi.2025.1707659 [author list to be added]

Glymphatic function in autism

Knudsen L.V. et al. (2026). Reduced glymphatic function in autism revealed by the diffusion tensor analysis along the perivascular space index.  Journal of Neural Transmission. DOI: 10.1007/s00702-026-03249-2